Skip to main content

Biosimilars

Biosimilars

Real-World Utilization of Infliximab and Its Biosimilars in Rheumatoid Arthritis

Biosimilars

Use of Multibiomarker Disease Activity Scores to Compare Biosimilar Adalimumab-afzb with EU-Sourced Reference Adalimumab in Patients with Active RA

Biosimilars

Switching to SB5 Biosimilar from Reference Adalimumab in Patients with RA, Axial Spondyloarthritis, or Psoriatic Arthritis

Biosimilars

Adalimumab Biosimilar PF-06410293 versus Reference Adalimumab in Patients with Moderate-to-Severe, Active Rheumatoid Arthritis

Biosimilars

Efficacy and Safety Equivalence of Proposed High-Concentration Adalimumab Biosimilar to Reference Adalimumab in Moderate-to-Severe, Active RA

Biosimilars

Switching to SB4 versus Continuation of Etanercept Reference in Patients with Rheumatoid Arthritis and Low Disease Activity

Biosimilars

Impact of Successive Switches of 2 Different Etanercept Biosimilars on Outcomes in Inflammatory Rheumatic Diseases

Biosimilars

Comparative Safety Analysis of Infliximab with Its Biosimilar Infliximab-dyyb in Pediatric Rheumatic Conditions

Biosimilars

Multibiomarker Disease Activity Scores as a Biosimilarity Assessment to Compare Biosimilar Infliximab-qbtx with Infliximab-EU in Patients with Active RA

Biosimilars

Phase 3 TROIKA Results Demonstrate Clinical Similarity Between HD201 and Trastuzumab Reference in HER2-Positive Early Breast Cancer

4
5
6
7
8

Page 7 of 8
Results 61 - 70 of 73